Clinical trial · Interventional
Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
NCT07189624CI-TRIAL-00099960ECHEFnot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known. Studying this production could help to provide relevant recommendations for training programming in these patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cirrhosis With Hepatocellular Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single arm
- description
- A single study visit will be required, during which the following will be caried out: * an assessment of physical condition: lower limb isometric strength test, liver frailty index, short physical performance battery, ultrasound assessment of quadriceps muscle mass * a 30-minutes exercise session on a bicycle (with heart rate monitor and gas exchange analyzer) * 3 fasting blood tests (before, at the end and 1 hour after the exercise) to assess the production of hepatokines and metabolites * measurements of perceived fatigue, muscle pain and effort (before, at the end and 1 hour after the exercise). Snacks will be served afterwards.
- interventionNames
- Other: Exercise
Primary outcomes (1)
- measure
- Systemic hepatokines rates (FGF-21 and follistatin)
- timeFrame
- Baseline (pre-exercise), immediately after exercise, 1 hour after the end of exercise
- description
- Blood samples
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular carcinoma developed on cirrhosis * Cirrhosis of any etiology, defined by a liver elasticity measurement \>15kPa or a history of cirrhosis decompensation * Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization * Child-Pugh scores A and B7 * WHO score ≤ 2 * Affiliation to french national social security system Exclusion Criteria: * Hepatic encephalopathy grade II or higher * Bone metastasis * Surgery performed within 30 days prior to inclusion visit * Liver transplant * Muscle injury within 3 months of inclusion * Pregnant or breast-feeding women * Patients under legal protection (guardianship, curatorship, safeguard of justice) * Participation in another clinical trial within 10 days of inclusion
References
Publications (0)
Data not yet available
No reference posted for this study.